It's Cheap and Pays a Big Dividend, But Is Viatris Stock a Buy?
Companies that produce generic drugs aren't known for being exciting investments, and there's little chance they'll ever expand as fast as your average tech stock or most other growth stocks. If they can manage to be a safer holding than faster-growing stocks, though, they can still be worthwhile to have in your portfolio, assuming you're looking for dividend cash flow and you're relatively risk-averse.
Viatris (NASDAQ: VTRS) is an up-and-coming generic manufacturer that could have the makings to be a good long-term holding, at least based on its 5.2% dividend. Let's explore whether this healthcare stock can live up to that promise and whether it's worth buying.
Ideally, an investment in a generic drug manufacturer like Viatris would have (at least) three features:
Source Fool.com
Viatris Inc. Aktie
Die Community ist unsicher über Viatris Inc.: Zu wenige Buy- und Sell-Einschätzungen vorhanden.
Das von der Community festgelegte Kursziel für Viatris Inc. von 12 € impliziert eine deutliche Steigerung gegenüber dem aktuellen Kurs von 9.8 €.
